Enrollment Complete in Thermocool Smarttouch® SF Catheter US IDE Study

Heart arrhythmia specialist company, Biosense Webster, Inc., has completed patient enrollment in its U.S. IDE study of the THERMOCOOL SMARTTOUCH® SF Catheter. The device is designed for the treatment of persistent atrial fibrillation (AF), an irregular heartbeat that lasts beyond seven days.


AF is the most common heart rhythm disorder and a leading cause of stroke among people 65 years and older. An estimated 3 million people in the U.S. and 20 million worldwide are affected. Left untreated, AF can lead to stroke, chronic fatigue, congestive heart failure and additional heart rhythm problems.

Johnson & Johnson family member Biosense Webster, Inc. tells us the THERMOCOOL SMARTTOUCH® SF Catheter, the most widely used ablation catheter on the market, was launched in 2016 in the United States to treat symptomatic, drug-refractory, paroxysmal AF, an intermittent AF that resolves within a week. The device combines contact force technology and a porous tip to optimize efficiency by providing uniform cooling at half the flow rate of earlier generation irrigated catheters, which eases the fluid management process.

The now fully enrolled Investigational Device Exemption (IDE) study is a prospective, multicenter, non-randomized evaluation of the catheter in 367 patients.

Investigator comments

“This is an important study that may lead to a new option for persistent AF patients in the United States who are unable to control their abnormal heart rhythm with drugs or tolerate the side effects these drugs can sometimes produce,” said investigator Moussa Mansour, MD, Director, Atrial Fibrillation Program, Massachusetts General Hospital (MGH) in Boston. “We’ve already seen very good results with the device in patients with paroxysmal AF and are now assessing whether it is beneficial to a wider patient population.”

“Catheter ablation is increasingly being offered to patients with atrial fibrillation based on the growing evidence supporting the procedure,” said Andrea Natale, MD, Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. “This study will add to our knowledge and potentially lead to greater adoption of RF ablation as a viable treatment option for patients with persistent AF.”

Company comments

“Biosense Webster, Inc. is a pioneer in catheter ablation technology,” said Shlomi Nachman, Company Group Chair of Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions. “Investing in clinical evidence to support indication expansion demonstrates our ongoing commitment to advancing treatment options for patients with AF.”

Source: Biosense Webster, Inc.

Share your thoughts

Your email address will not be published. Required fields are marked *